The effect of melatonin on quality of sleep in patients with sleep disturbance admitted to post coronary care units: A randomized controlled trial.
Coronary Care Units
Heart Diseases
Melatonin
Sleep Disorders
Journal
BioMedicine
ISSN: 2211-8020
Titre abrégé: Biomedicine (Taipei)
Pays: China (Republic : 1949- )
ID NLM: 101611451
Informations de publication
Date de publication:
2021
2021
Historique:
received:
07
08
2020
accepted:
28
08
2020
entrez:
28
2
2022
pubmed:
1
3
2022
medline:
1
3
2022
Statut:
epublish
Résumé
Patients with cardiovascular disease who required to be admitted in coronary care units (CCU) would have sleep deprivation. During the admission some factors such as continuous ambient light exposure can suppress melatonin release, in consequence sleep deprivation will be occurred and hinder the progress of patients' treatment. The aim of study was to evaluate the effect of melatonin on the sleep quality of patients admitted to post-CCU. This randomized clinical trial was carried out on 110 patients admitted to post-CCU at SayyadeShirazi Hospital, Gorgan, Iran. Patients with a poor sleep quality (Pittsburgh sleep quality index (PSQI) global score>5) were randomly allocated into two intervention and placebo groups. Patients in the intervention group received melatonin (3 mg; 30 minutes before bedtime), and the placebo group received placebo for 2 weeks, and their sleep quality was re-evaluated after the end of intervention. Data were analyzed using paired The results showed that mean of the patients' PSQI scores decreased significantly in intervention group (from 14.95 ± 1.48 to 11.65 ± 1.50, P < 0.001), while in placebo group the difference was not significant (from 15.48 ± 1.47 to 15.24 ± 1.71, P = 0.129). Post-intervention score of patients in intervention group was also lower than the placebo group (P < 0.001). The melatonin can improve the sleep quality of the patients admitted to post-CCU who suffer from sleep disturbance.
Sections du résumé
BACKGROUND AND OBJECTIVES
OBJECTIVE
Patients with cardiovascular disease who required to be admitted in coronary care units (CCU) would have sleep deprivation. During the admission some factors such as continuous ambient light exposure can suppress melatonin release, in consequence sleep deprivation will be occurred and hinder the progress of patients' treatment. The aim of study was to evaluate the effect of melatonin on the sleep quality of patients admitted to post-CCU.
MATERIALS AND METHODS
METHODS
This randomized clinical trial was carried out on 110 patients admitted to post-CCU at SayyadeShirazi Hospital, Gorgan, Iran. Patients with a poor sleep quality (Pittsburgh sleep quality index (PSQI) global score>5) were randomly allocated into two intervention and placebo groups. Patients in the intervention group received melatonin (3 mg; 30 minutes before bedtime), and the placebo group received placebo for 2 weeks, and their sleep quality was re-evaluated after the end of intervention. Data were analyzed using paired
RESULTS
RESULTS
The results showed that mean of the patients' PSQI scores decreased significantly in intervention group (from 14.95 ± 1.48 to 11.65 ± 1.50, P < 0.001), while in placebo group the difference was not significant (from 15.48 ± 1.47 to 15.24 ± 1.71, P = 0.129). Post-intervention score of patients in intervention group was also lower than the placebo group (P < 0.001).
CONCLUSION
CONCLUSIONS
The melatonin can improve the sleep quality of the patients admitted to post-CCU who suffer from sleep disturbance.
Identifiants
pubmed: 35223393
doi: 10.37796/2211-8039.1123
pii: bmed-11-01-034
pmc: PMC8823467
doi:
Types de publication
Journal Article
Langues
eng
Pagination
34-40Informations de copyright
© the Author(s).
Références
Nutr J. 2014 Nov 07;13:106
pubmed: 25380732
Br J Pharmacol. 2018 Aug;175(16):3190-3199
pubmed: 29318587
PLoS One. 2013 May 17;8(5):e63773
pubmed: 23691095
Dev Med Child Neurol. 2011 Sep;53(9):783-792
pubmed: 21518346
Saudi J Anaesth. 2011 Oct;5(4):395-410
pubmed: 22144928
Prog Neuropsychopharmacol Biol Psychiatry. 2011 Jun 1;35(4):913-23
pubmed: 21453740
J Pineal Res. 2000 Aug;29(1):34-9
pubmed: 10949538
J Intensive Care Med. 2016 Aug;31(7):451-5
pubmed: 26092575
Health Qual Life Outcomes. 2012 Jun 18;10:72
pubmed: 22709334
Open Access Maced J Med Sci. 2018 Dec 17;6(12):2342-2347
pubmed: 30607188
Trials. 2014 Aug 18;15:327
pubmed: 25135124
Colo Nurse. 2013 Nov;113(4):4
pubmed: 24597000
Indian J Nephrol. 2013 Jul;23(4):264-9
pubmed: 23960341
J Sleep Res. 2012 Aug;21(4):427-33
pubmed: 22151079
Chronobiol Int. 2015;32(6):875-9
pubmed: 26102093
Iran J Nurs Midwifery Res. 2010 Fall;15(4):234-9
pubmed: 22049287
Int J Mol Sci. 2014 Sep 09;15(9):15924-50
pubmed: 25207602
Cochrane Database Syst Rev. 2018 May 10;5:CD012455
pubmed: 29746721
Crit Care. 2015 Mar 19;19:124
pubmed: 25887528
Breast Cancer Res Treat. 2014 Jun;145(2):381-8
pubmed: 24718775
Curr Neuropharmacol. 2017 Apr;15(3):434-443
pubmed: 28503116
Neurology. 2010 May 25;74(21):1732-8
pubmed: 20498441
PLoS One. 2013 Nov 25;8(11):e81261
pubmed: 24282576
Crit Care. 2008;12(2):R52
pubmed: 18423009
Neurotherapeutics. 2012 Oct;9(4):687-701
pubmed: 22976557
Tanaffos. 2013;12(2):9-15
pubmed: 25191456
Am J Addict. 2015 Oct;24(7):590-8
pubmed: 26346395
J Clin Nurs. 2012 Mar;21(5-6):728-35
pubmed: 22082250
J Clin Exp Neuropsychol. 2014;36(7):691-700
pubmed: 24931450
Crit Care. 2010;14(2):R66
pubmed: 20398302
Arch Gerontol Geriatr. 2011 Mar-Apr;52(2):133-7
pubmed: 20338647
Curr Pharm Des. 2011;17(15):1471-5
pubmed: 21476952
Eur Neuropsychopharmacol. 2011 Sep;21 Suppl 4:S683-93
pubmed: 21835596
Psychol Bull. 2016 Sep;142(9):969-990
pubmed: 27416139